EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments

Toshimasa Shimizu, Shin-Ya Kawashiri, Tomohiro Koga, Rieko Kiya, Michiko Morita, Shohei Kuroda, Shigeki Tashiro, Shuntaro Sato, Hiroshi Yano, Tomoyuki Asano, Kazuyoshi Saito, Tamami Yoshitama und 12 weitere

Drug Discoveries & Therapeutics · 2025

DOI: 10.5582/ddt.2025.01044 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Drug Discoveries & Therapeutics, 2025. Verfasst von Toshimasa Shimizu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Scien…. Hauptthemen laut MEDLINE: Infliximab, Arthritis, Rheumatoid, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabArthritis, RheumatoidBiosimilar PharmaceuticalsAntirheumatic AgentsAntibodies, MonoclonalHumansFemaleMaleMiddle AgedProspective StudiesRemission InductionBiomarkersAdultUltrasonographyAgedDrug SubstitutionTreatment OutcomeJapanEast Asian People

Stichwörter der Autor:innen

CT-P13biomarkerbiosimilarmusculoskeletal ultrasoundrheumatoid arthritis

Substanzen

InfliximabBiosimilar PharmaceuticalsAntirheumatic AgentsCT-P13BiomarkersAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Naga-saki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Internal Medicine, Tobata General Hospital, Kitakyushu, Japan.
  • Yoshitama Clinic for Rheumatic Diseases, Kagoshima, Japan.

Zitieren

APA

Shimizu, T., Kawashiri, S. Y., Koga, T., Kiya, R., Morita, M., Kuroda, S., Tashiro, S., Sato, S., Yano, H., Asano, T., Saito, K., Yoshitama, T., Ueki, Y., Eiraku, N., Yamada, Y., Okano, T., Ushio, Y., Dobashi, H., Itami, T., …, & Kawakami, A. (2025). Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2025.01044

Vancouver

Shimizu T, Kawashiri SY, Koga T, Kiya R, Morita M, Kuroda S, et al. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Drug Discoveries & Therapeutics. 2025. doi:10.5582/ddt.2025.01044

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Toshimasa and Kawashiri, Shin-Ya and Koga, Tomohiro and Kiya, Rieko and Morita, Michiko and Kuroda, Shohei and Tashiro, Shigeki and Sato, Shuntaro and Yano, Hiroshi and Asano, Tomoyuki and Saito, Kazuyoshi and Yoshitama, Tamami and Ueki, Yukitaka and Eiraku, Nobutaka and Yamada, Yutaro and Okano, Tadashi and Ushio, Yusuke and Dobashi, Hiroaki and Itami, Tetsu and Tomita, Daisuke and Nozaki, Yuji and Hosogaya, Naoki and Yamamoto, Hiroshi and Kawakami, Atsushi},
  title = {Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments},
  journal = {Drug Discoveries & Therapeutics},
  year = {2025},
  doi = {10.5582/ddt.2025.01044}
}
Kostenlos starten →